It's now more than three decades (counting from 1989) since the US FDA (the United States Food and Drug Administration) approved the first monoclonal antibodies. During this period, antibody engineering has constantly evolved.
Because of the adoption of the latest antibody production methods and specificity, today's antibodies pose fewer adverse effects, positioning them as one of the best-selling medications in the pharmaceutical market. The global antibody market stands at $237 billion in 2023 and will reach $834 billion in 2033, growing at a 13.4% CAGR, as determined by Future Market Insights.
The recombinant antibody is the newest yet most advanced antibody in the market today. Ideally, technologies have considerably contributed to recombinant antibody production and optimization.
Some of these advancements include the generation of hybridomas, Antibody Sequencing Services, deep sequencing, protein display technologies, Peptide Synthesis Services, and DNA technology in antibody production. Combining these technologies in antibody production has enhanced antibody discovery platforms and optimization of recombinant antibodies to be a successful and standard endeavor.
This article will look at the recent advances in recombinant antibody production technology and anything related to recombinant antibody engineering.
We'll start with the basics!
What is an Antibody?
A recombinant antibody is an antibody, right? So, before focusing on recombinant antibody production technologies, it's essential to understand what an antibody is, what antibody sequencing services are, which antibody-sequencing companies exist, and any other basic but necessary information.
Antibodies, known as immunoglobulins, are Y-shaped protein molecules secreted by B cells, primarily differentiated into plasma cells. The basic function of antibodies is to neutralize and control pathogens while enhancing the immune response.
Moreover, antibody production facilitates protection against intoxication and infection by various mechanisms of antibody functionality, such as agonism, antagonism, lysosome-related programmed cell death (PCD), apoptotic PCD, antibody-dependent cellular phagocytosis (ADCP), antibody-dependent cellular cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC).
As stated earlier, the history of antibody engineering and production dates back to the 1980s, when scientists were exploring the possibility of using antibodies as therapeutics.
One significant milestone during this period was the development of hybridoma technology and the use of natural sources, such as animal blood, as diagnostic agents. This facilitated the production of monoclonal antibodies through the fusion of B cells with myeloma cells, enhancing the generation of a single antibody type.
While the production of feasible antibodies was possible at this stage, it was often restricted because many hybridomas were low-yielding and unstable, and suitable myeloma cell lines were unavailable.
For this reason, antibody discovery, a fundamental aspect that expands clinical applications and research, led to the emergence of recombinant antibody production, aimed at improving antibody engineering opportunities and experimental reproducibility.
So, let's delve deeper into recombinant antibodies!
What are Recombinant Antibodies?
For a long time, polyclonal and monoclonal antibodies have been commercially available until recently, when they have been complemented by the enormous production of recombinant antibodies. A distinction between monoclonal and polyclonal antibodies is basically found in the number of epitopes, a significant functionality influencer.
Polyclonal antibodies require multiple epitopes to provide signal amplification, while monoclonal antibodies recognize only one epitope, eventually producing more reproducible effects.
Recombinant antibodies, however, provide greater benefits, including enabling more scalable production, increasing capacity to accommodate experimental needs, and enhancing consistency. Therefore, these antibodies are manufactured using synthetic genes and don't require animals as raw materials, as is the case with monoclonal antibodies.
Recombinant antibody production is carried out by ELISA kit manufacturers and primarily depends on antibody expression system laboratories, Protein Expression and Production Services, and Protein Expression and Purification Services.
ELISA kits, often known as ELISA test kits, facilitate the production of homogeneous, high-quality recombinant antibodies with standard features and capabilities to suit different applications.
Ideally, the antibodies are designed to fit specific epitopes to ultimately boost specificity, affinity, and stability. Because of this high quality and fast production, recombinant antibodies qualify as highly efficient in biopharmaceutical manufacturing.
How is Recombinant Antibody Production Done?
Recombinant antibody production is a method that uses genetic engineering techniques to produce antibodies in vitro. Ideally, it involves custom gene synthesis, a cost-effective and reliable method often used by protein synthesis companies.
Gene synthesis services typically allow for the cloning of genes and combining them to develop antibodies with unique features and functionalities.
Since antibodies are proteins, particularly immunoglobulins, IgG antibodies are produced by B cells following their action against bacteria and viruses. Each antibody contains two light chains and two heavy chains. Each chain has a variable region and a constant region to facilitate binding and recognition of various targets called antigens.
Moreover, recombinant antibody production involves encoding genes to resonate with a target antibody, eventually enhancing protein expression and production services and protein expression and purification services.
After the genes encode for the light and heavy chains of the target antibody, they are introduced into host cells through transfection. Next, the host cells secrete and produce antibodies that can be purified and used in different capacities, including treatments and diagnostic assays.
The comparison between traditional and recombinant antibody production techniques is undoubtedly evident and requires no further explanation. Ideally, recombinant antibody production is more advantageous.
For example, recombinant antibody production technology allows the development of fully human or humanized antibodies, which is impossible with other antibody production methods.
This makes it less likely to trigger an immune response, making it appropriate for therapeutic applications. In addition, it facilitates the production of large quantities of antibodies with the flexibility to suit specific applications optimally.
The Process of Recombinant Antibody Production
The following is the process followed in recombinant antibody production technology.
1. Targeting a Specific Antigen
Protein Production Companies and peptide synthesis companies usually start by identifying a specific antigen that the antibody is designed to bind to and recognize appropriately.
2. Developing an Antibody Library
An antibody library is developed to enable antibody screening after targeting a specific antigen. The library contains multiple fragments, each with a specific binding ability and sequence, and antibody sequencing companies create it to match a potential antibody with the intended antigen.
3. Screening Antibodies
The next step in recombinant antibody production involves screening the antibodies to identify fragments that bind successfully to the required antigen. The techniques employed in this step often include yeast surface display and phage display.
4. Antibody Engineering
Following the above steps, it's time for antibody engineering and, ultimately, optimization to increase affinity, specificity, and stability toward the antigen in question. Antibody fusion and site-directed mutagenesis are the most common techniques used in this step.
5. Expression and Purification
The process ends with protein expression and purification, often done using chromatography-based purification after mammalian cell expression.
Common Types of Recombinant Antibodies
Recombinant antibodies exist in three major forms: single-domain antibody (sdAb), single-chain fragment variable (scFv), and Fab.
Starting with sdAb, these are recombinant antibodies discovered in nurse sharks and camelids with a lone VH (variable heavy) domain; however, they lack a paired VL (variable light) domain. A notable advantage of domain antibodies is that they have better stability characteristics and folding, as well as a smaller size and the absence of a linker.
Next is the scFv, antibodies that combine the VL sequence with the VH sequence in a single gene construct. The resulting polypeptides, with heavy and light variable chains, are connected by a peptide linker to facilitate the functionality of the antigen-binding sites.
In addition, linker technology is necessary for antibody library screening. Therefore, scFvs are also independently developed as components of drug candidates and therapeutic constructs.
Finally, Fab fragments, originally related to cleavage products obtained by treating rabbit antibodies with papain, ultimately produce intact Fc regions and identical Fab fragments. A Fab molecule has four domains, including the light-chain variable domain associated with the light-chain constant domain, and the heavy-chain variable domain associated with the heavy-chain constant domain 1.
One more thing, Fab molecules have a hinge region that allows flexibility relative to the intact IgG Fc region and enables the antibodies to crystallize, making them suitable for diffraction studies. That’s why, to date, only a few structures of full IgGs are known.
Why Embrace Recombinant Production Technology?
Polyclonal and monoclonal antibodies have indeed been on the market for longer. However, recombinant antibodies have taken the market by storm, primarily due to the reproducibility crisis that has challenged publishers and researchers to seek more clarity concerning antibody provenance.
Furthermore, recombinant antibody production has increased in efforts to reduce assay signal variation, improve specificity, and determine actual monospecificty.
In addition, recombinant DNA technology allows precise engineering of antibodies to enhance their binding affinity and therapeutic potential. This includes the creation of bispecific antibodies, which can simultaneously target two different antigens, opening up new possibilities for treating complex diseases.
Other reasons for protein synthesis companies to embrace recombinant production technology include guaranteed long-term supply, top-notch batch-to-batch consistency, and the rapid nature of the process, which helps avoid the need for animal use. Not to mention, their versatility in serving different needs makes them suitable for antibody engineering.
Advances in Recombinant Antibody Production
Starting from monoclonal antibodies to polyclonal antibodies and ultimately to recombinant antibodies, it's evident that there have been significant advances in each stage. Every case focuses on enhancing efficiency and achieving perfect-fit applications between antibodies and antigens.
Let's look at some of the most pivotal advances and their significance:
1. DNA Cloning
Recombinant DNA technology in antibody production is integral to recombinant antibody production. DNA cloning involves custom gene synthesis and inserting the antibody gene (or variable regions) into a vector, which can be expressed in host systems.
This allows for precise control of antibody gene sequences, enhancing the customization of antibodies for specific targets. Furthermore, the process facilitates the creation of fully human antibodies, reducing the risk of immune reactions in patients.
2. Generation of Hybridomas
Although hybridoma technology pioneered monoclonal antibody development by protein production companies, it also secured a place in recombinant antibody production technology.
Ideally, hybridoma technology involves fusing antibody-producing B cells with myeloma cells to create immortalized cell lines that produce a single type of antibody.
3. Polymerase Chain Reaction (PCR)
Another advance in recombinant antibody production technology? Through PCR, a molecular biology technique, antibody sequencing services can generate clones for antibody genes with more precision.
Because of its accurate and rapid amplification of specific antibody genes, this technology has significantly improved the efficiency of creating recombinant antibodies with customized sequences.
4. Peptide and Protein Display Technologies
Technologies like phage display, yeast display, and ribosome display enable the presentation of antibody fragments on the surface of microorganisms. In addition, they allow antibody library screening and the selection of antibodies with high affinity for specific antigens.
As a result, a broader library of antibody variants that allows for screening of binding characteristics is achieved, ultimately leading to highly specific and effective antibodies.
5. Deep Sequencing
Last but not least, the advances in recombinant antibody technology enhance Antibody Sequencing Services. Typically, deep sequencing allows for analysis of diverse antibody repertoires and supports custom gene synthesis, allowing researchers to select the most promising candidates for further development.
Conclusion
Recombinant antibody production is emerging as the focal point for diagnostics and research and a growing class for custom protein synthesis. Antibody development has been consistently transformed by in vitro selection systems, and more recombinant technology systems continue to be generated.
Today, more and more therapeutic antibodies are produced in mammalian systems to mitigate immunogenicity risks associated with non-human glycosylation formats.
While the wholesale focus on recombinant antibody production in the therapeutic arena started close to two decades ago, it's now picking up pace, and it's all thanks to technological advances. Whereas recombinant antibodies were a mere dream, they are now available from many suppliers; it's unlikely you can fail to find one at any time.
If you're a researcher, scientist, or innovator, take the next step in antibody research and development. As you've witnessed the remarkable evolution of recombinant antibody production, exploring the endless possibilities of this cutting-edge technology is integral. Whether you are working in diagnostics, therapeutics, or research, the advances in antibody engineering and production offer new opportunities for precision medicine and healthcare.
Visit Biomatik to discover a wide range of products and services that can support your antibody research and development needs. Biomatik provides the tools and expertise to advance your projects from custom antibody production to DNA sequencing and protein synthesis.